| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2823789 | Multiple Sclerosis and Related Disorders | 2016 | 7 Pages |
Abstract
Decreased serum concentrations of sVCAM-1 and altered whole blood mRNA expression levels of a panel of immunomarkers, associated with natalizumab-treatment, are not sensitive markers of MS disease activity. However, decreased expression of pro-inflammatory HLX1 and IL1B and increased expression of immunoregulatory EBI3 may indicate a less pathogenic immune activation status in natalizumab-treated MS.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
ER. Petersen, HB. Søndergaard, AB. Oturai, PEH. Jensen, PS. Sorensen, F. Sellebjerg, L. Börnsen,